EHS
EHS

STAT+: Pharmalittle: Pfizer and BioNTech to boost Covid-19 vaccine production; lawmakers ask FTC to probe insulin pricing



Rise and shine, another busy day is on the way. There is a rhythm to such observations, since our short person is, once again, hunched over a laptop for remote learning and our official mascot is snoozing cozily in a corner. As for us, we are firing up the trusty coffee kettle for yet another cup of needed stimulation. Our choice today is cinnamon mocha. Please feel free to join us. Meanwhile, here is the latest grab bag of interesting items. We hope your day is productive and enjoyable. And keep us in mind for any saucy tidbits that float by. …

BioNTech (BNTX) disclosed that, along with its partner, Pfizer (PFE), it would increase manufacturing capacity of their Covid-19 vaccine to 2.5 billion doses by the end of 2021, unveiling for the first time projected sales of close to $11.73 billion from the product this year, Reuters writes. Pfizer previously said the companies would likely produce between 2.3 billion and 2.4 billion doses this year. As of last week, more than 200 million doses have been supplied, while signed orders for delivery in 2021 currently amount to 1.4 billion doses.

Continue to STAT+ to read the full story…

Source link

EHS
Back to top button